Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Viking Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Viking Therapeutics, Inc.’s stock price such as:

• Viking Therapeutics, Inc.’s current stock price and volume
• Why Viking Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for VKTX from analysts
• VKTX’s stock price momentum as measured by its relative strength

About Viking Therapeutics, Inc. (VKTX)

Before we jump into Viking Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Want to learn more about Viking Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Viking Therapeutics, Inc..

Viking Therapeutics, Inc.’s Stock Price as of Market Close

As of April 29, 2026, 4:00 PM, CST, Viking Therapeutics, Inc.’s stock price was $31.330.

Viking Therapeutics, Inc. is down 3.27% from its previous closing price of $32.390.

During the last market session, Viking Therapeutics, Inc.’s stock traded between $31.150 and $32.380. Currently, there are approximately 114.01 million shares outstanding for Viking Therapeutics, Inc..

Viking Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Viking Therapeutics, Inc. Stock Price History

Viking Therapeutics, Inc.’s (VKTX) price is currently down 3.72% so far this month.

During the month of April, Viking Therapeutics, Inc.’s stock price has reached a high of $36.790 and a low of $31.150.

Over the last year, Viking Therapeutics, Inc. has hit prices as high as $43.150 and as low as $22.959. Year to date, Viking Therapeutics, Inc.’s stock is down 10.94%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Viking Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 29, 2026, there was 1 analyst who downgraded Viking Therapeutics, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Viking Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Viking Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Viking Therapeutics, Inc. (VKTX) by visiting AAII Stock Evaluator.

Relative Price Strength of Viking Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 29, 2026, Viking Therapeutics, Inc. has a weighted four-quarter relative price strength of -2.22%, which translates to a Momentum Score of 49 and is considered to be Average.

Want to learn more about how Viking Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Viking Therapeutics, Inc. Stock Price: Bottom Line

As of April 29, 2026, Viking Therapeutics, Inc.’s stock price is $31.330, which is down 3.27% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Viking Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.